Guest Editor

Oncogene (2002) 21, 8535. doi:10.1038/sj.onc.1206079

Ralph Arlinghaus

Dr Ralph B Arlinghaus, Professor and Chairman of the Department of Molecular Pathology at the University of Texas M. D. Anderson Cancer Center, is known for his studies on RNA tumor viruses (retroviruses), the v-Mos oncoprotein, and the role of Bcr in Bcr-Abl positive human leukemia. Dr Arlinghaus attended the University of Cincinnati receiving a B.S. in Pharmacy in 1957 (valedictorian), a M.S. degree in Pharmaceutical Chemistry in 1959

and a Ph.D. in Biological Chemistry in 1961. Dr Arlinghaus extended his training as a postdoctoral fellow in Dr Richard Schweet's laboratory at the University of Kentucky Medical School, Department of Biochemistry from 1961–1965, where he made contributions in the area of peptide bond formation on ribosome/mRNA complexes; he was first to establish the two-site model for peptide bond formation. Dr Arlinghaus then accepted a position at the Plum Island Animal Disease Laboratory as a Research Chemist where he did research on Foot-and-Mouth disease virus from 1965–1969. Dr Arlinghaus moved to Houston, Texas in 1969 to accept a position in the Department of Biology at the University of Texas M.D. Anderson Hospital and Tumor Institute. During 1971–1980, he made contributions to the field of mouse RNA tumor viruses including mechanisms involved in producing *gag* proteins, the suppression of a termination codon involved in producing the *gag-pol* precursor, and steps involved in producing the SU and TM viral envelope proteins. He also published an overall model describing the formation of mouse retroviral proteins. Later in 1983, he focused his studies on the v-Mos protein, discovering its serine/threonine protein kinase activity. In 1983, Dr Arlinghaus joined Johnson and Johnson as Director of Vaccine Development at the Johnson and Johnson Biotechnology Center, Inc. in La Jolla. In addition, he was a visiting Investigator (Member) at the Scripps Clinic and Research Foundation in La Jolla. In July of 1986, Dr Arlinghaus returned to M.D. Anderson as Professor and Chairman of the Department of Molecular Pathology. In recent years he focused his efforts on the Bcr-Abl oncoprotein and the interaction between Bcr and Abl proteins. He is the author of more than 230 journal publications and book chapters, and he currently serves on the Editorial Boards for *Oncogene* and the *International Journal of Oncology*. He currently holds the Stringer Chair in Cancer Research.